Regulations of Calneurin Sense

c

Identifiers

FormulaC5H13NO·CAS463-88-7·EC100.006.67

How does the regulatory treatment of calneurin sense differ by market or product category?

Regulatory treatment differs sharply between the US and EU. In the US, calneurin sense is listed on the TSCA Inventory as a non-confidential substance and is subject to an active TSCA 5(a) Final SNUR, indicating EPA has imposed significant new use rules. In the EU, it is listed as restricted under REACH Annex XVII, though the specific entry is not fully specified in the available evidence. This means a US launch requires SNUR compliance, while an EU launch must identify and satisfy the exact Annex XVII restriction conditions. Product category is not differentiated in the evidence, so the same restrictions appear to apply across categories unless further data specify otherwise.

Which United States federal regulations apply to Calneurin sense?

1 regulation

EPA TSCA Regulatory Flag

jurisdiction: United States (US); framework: TSCA Inventory (Toxic Substances Control Act); listing_status: Contains non-confidential chemical substance listings on the TSCA Inventory; updated approximately every six months; 86,862 chemicals total, 42,578 active (as of July 2025 update); annex_or_entry: Inventory listings with fields such as ACTIVITY, CASRN, casregno, ChemName, DEF, EXP, FLAG, ID, UID, UVCB; special flags (e.g., FRI, PE1, PE2, PE3, R, S, SP, T, TP, XU, Y1, Y2) indicate regulatory or exemption status

What EU regulatory requirements apply to Calneurin sense?

1 regulation

REACH Restricted Substance

jurisdiction: EU; framework: REACH Annex XVII restriction (Substances restricted under REACH); listing_status: restricted; annex_or_entry: Entry not fully specified in provided text excerpt; the page is the REACH Annex XVII listing of restricted substances

Which conditions, limits, and use contexts most affect a compliance assessment for calneurin sense?

The most material conditions are the active TSCA 5(a) Final SNUR in the US and the REACH Annex XVII restriction in the EU. The SNUR implies that any new use not already covered by the SNUR requires prior EPA review and potentially a significant new use notice. The REACH restriction imposes binding limits, but the exact entry and numerical limits are not specified in the evidence. Additionally, the GHS classification of H350 (may cause cancer) via inhalation and dermal routes is a hazard condition that affects labeling, safety data sheets, and exposure controls. No quantitative exposure limits are available, so compliance cannot be tied to specific threshold values.

What should be in place before a product containing calneurin sense is assessed for launch?

Before launch assessment, the following should be in place: confirmation of the exact TSCA 5(a) SNUR terms and whether the intended use is a significant new use; identification of the specific REACH Annex XVII entry and its restriction conditions for EU markets; and a GHS-compliant hazard communication package reflecting the H350 carcinogenicity classification. Documentation should include the substance's CAS number (463-88-7) and EC number (100.006.67) for regulatory filings. Since the evidence does not specify product-category exemptions or use-specific limits, a full regulatory dossier must be compiled from official sources before any compliance determination.

Where does the available regulatory position stop short of supporting a decision on calneurin sense?

The available regulatory position stops short of supporting a launch decision because the REACH Annex XVII entry is not fully specified, leaving the exact restriction conditions unknown. The TSCA SNUR is active but its specific use restrictions and notification requirements are not detailed. The GHS H350 classification indicates carcinogenicity, but no exposure limits or risk management measures are provided. These gaps mean that while the substance is clearly regulated in both the US and EU, the precise compliance obligations cannot be determined from the evidence alone. A decision would require obtaining the full regulatory texts and possibly a formal regulatory review.

Which recent regulatory changes or effective dates are material for calneurin sense?

The TSCA Inventory update as of July 2025 is a recent change, reflecting the current listing status of calneurin sense. The active TSCA 5(a) Final SNUR is an ongoing regulatory action, but no effective date or recent amendment is provided. The REACH Annex XVII restriction is listed as current, but no recent change or effective date is specified. Therefore, the only material date is the July 2025 TSCA Inventory update, which confirms the substance's active listing. For EU compliance, the absence of a specific entry date means the restriction should be treated as currently in force, but its effective date cannot be confirmed from the evidence.